Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>Events>This Event
  Events - November 2012

Introduction to Sterile Product Manufacture for New Starters and Junior Staff (2 day)

28 Nov 2012 - 29 Nov 2012 - Window Conference Venue, 13 Windsor Street, Islington, London, N1 8QG

Bookmark and Share

Course objectives
To provide training to personnel who are new to the Pharmaceutical or Biotech Industries and have no understanding of cGMP and who intend to work with sterile products, development, manufacturing, registration and facilities.

The course will include:
• A comprehensive background in sterile product manufacturing, regulations and facilities. • Adherence to cGMP and the consequences for non-compliance. • How to initiate development of new formulations, manufacturing, environmental and product monitoring. • Modes of sterilization and types of products.

Who should attend?
The course is ideal for new starters or junior staff working in the Pharmaceutical or Biotech industries who will be exposed to a sterile manufacturing facility or who will be involved in the development of new products. This is an introductory course and the level of detail will be as a broad based overview.
• Clinical Trials Manufacturing Scientists
• Development Scientists
• Regulatory Affairs Personal
• Pharmaceutical Production Personnel
• Quality Control and Quality Assurance Personnel

Course Programme:
Day One (9am – 5pm)
• What is a sterile product?
• Classification of products.
• Why are they sterile?
Basic microbiology. The Regulatory environment.
• cGMP
• Facilities and processing.
• The impact of personnel and materials
• Environmental Monitoring.
• What is the difference and the impact or viable and non-viable contaminants.
Day Two (9am – 5pm)
• Dosage Forms: syringes, ampoules, vials and others
• Sterilisation: Overview of methods of sterilisation, autoclave, dry heat oven, radiation, filtration and EtOH exposure.
• Aseptic vs. Terminally sterilized, how do you decide?
• Areas of specialization. Where do I go from here?

Course Speaker
Paul Cummings
Paul is a Chartered Biologist, a Fellow Member of the Society of Biology and has nearly 30 years experience in the Pharmacy/Pharmaceutical Industry and left GSK in 2009 to pursue a career as an Independent Consultant. His latter roles at GSK were “Head of Sterile Product Clinical Trial Supplies” and “Director of Product Development”, working on new chemical entities from candidate selection through to market launch and product line extensions. He has broad international experience of product transfers, manufacturing and registrations and can provide an invaluable resource to any company.

Discounted rate for registering and paying before 3 October 2012 - 2 day course £1062.00 (+ VAT if applicable, see VAT NOTES)
Full Fee: 2 day course £1180.00 (+ VAT if applicable, see VAT NOTES)
Discount of 10% applies for booking more than 1 delegate. Discount of 10% applies for booking more than 1 course. Maximum discount received is 15%

Further information
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos